What changed
$MDT — WATCHLIST 📊 | 6 MONTHS THESIS
🧭 Monitoring — no confident call yet
🎯 FQ4 FY2027 (ends Apr) | reported Jun 03 | Rev $9.0B | EPS $1.55 vs $1.56 🔴 | Margin 24.3%
💡 The market sees a low-growth, debt-laden giant and prices it at 13x P/E. My variant view acknowledges the slight EPS miss but notes revenue resilience and margin stability. The debt overhang is real, but the low multiple may already discount it; no deep undervaluation exists.
🏢 Business Quality: 6/10
📊 Valuation: fair — trading at 13.1x trailing P/E, within a 12-14x range on forward EPS of ~$6.40, which aligns with low-growth med-tech peers.
🔮 Catalyst: Next quarterly earnings release
⚖️ Watchlist: Modestly priced but no clear catalyst to re-rate given high debt and weak quant momentum; wait for debt reduction or earnings acceleration before acting.